Getting Diagnosed

Steps to a DMD diagnosis.

On average, obtaining a confirmed Duchenne diagnosis takes about 2.5 years from the time symptoms are first noticed. Diagnosis is the vital first step in managing Duchenne, so it’s important to obtain a diagnosis as early as possible—before additional muscle damage occurs.

Image
Nicholas, age 17 Amenable to exon 53 skipping

Meet Nicholas, age 17
Amenable to exon 53 skipping

Common steps to a Duchenne diagnosis.
 

Common steps to a Duchenne diagnosis: Noticing symptoms | Initial diagnosis | Confirmed diagnosis


Parents, caregivers, or teachers


If you or others are seeing telltale signs of Duchenne, such as large calves or Gowers maneuver, trust your gut and check in with your child’s doctor. See the symptoms of Duchenne.


Family doctor or pediatrician


Ask the doctor for a creatine kinase, or CK, blood test. This is a simple, highly accurate test for indicating muscle damage that can result from Duchenne. A CK test can’t confirm Duchenne or identify the mutation—only a genetic test can. Learn more about genetic testing.


Pediatric neurologist or neuromuscular specialist

Genetic testing will determine if a mutation is present on the dystrophin gene that would indicate Duchenne. It can also identify the type of mutation—which is important for determining potential clinical trial participation or therapy options. Explore sample test results.

 

Icon Alert

These are the common steps to a diagnosis, but your path may be different. The important things are arming yourself with information on tests that can diagnose Duchenne and talking to your doctor as soon as your child displays the signs. 

     

We’ve developed a Doctor Discussion Guide to help you start that important conversation. Get a personalized guide

Why a timely diagnosis matters.

With Duchenne, symptoms such as muscle weakness and loss of mobility are progressive, and unfortunately, muscle damage is irreversible. The earlier you know the diagnosis, the sooner you can start the conversation about disease management with your child’s doctor. You’ll know your options after genetic testing that will confirm Duchenne and identify the specific mutation in the dystrophin gene. Learn more about treatment with VYONDYS 53.

2.5

years

The average time from seeing the first signs to a Duchenne diagnosis.

~5

years old

The average age of children diagnosed with Duchenne.

Luke, age 12 Amenable to exon 53 skipping
Image
Desktop star

Sign up to get updates
from Sarepta.  

Related FAQs

Where do I get a genetic test?

If your child has been diagnosed with Duchenne, you can request a genetic test through your child’s doctor. Once you have the results, your doctor or a genetic counselor can interpret them for you. Find out more about genetic testing for Duchenne.

We have a genetic test. How do I know if my child can be treated with VYONDYS 53?

A doctor will need to interpret the test results to consider appropriate treatment options. Learn more about deletions.

Read More

 

WHAT IS VYONDYS 53 (golodirsen)?

VYONDYS 53 is used to treat patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene that can be treated by skipping exon 53.

This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

IMPORTANT SAFETY INFORMATION

Contraindications: Do not receive VYONDYS 53 if you are allergic to golodirsen or any of the ingredients in VYONDYS 53. Serious allergic reactions to golodirsen have included anaphylaxis, which may include difficulty breathing and tightness in the chest.

Hypersensitivity Reactions: Serious allergic reactions, including anaphylaxis, have occurred in patients who were treated with VYONDYS 53. Additional allergic reactions, including rash, fever, itching, hives, and inflammation and/or peeling of the skin have occurred in patients who were treated with VYONDYS 53. Patients should seek immediate medical care should they experience signs and symptoms of allergic reaction. Your doctor will institute appropriate medical treatment which may include slowing, interrupting, or discontinuing the VYONDYS 53 infusion. Your doctor will monitor you until the condition resolves.

Read More

IMPORTANT SAFETY INFORMATION

Contraindications: Do not receive VYONDYS 53 if you are allergic to golodirsen or any of the ingredients in VYONDYS 53. Serious allergic reactions to golodirsen have included anaphylaxis, which may include difficulty breathing and tightness in the chest.

Hypersensitivity Reactions: Serious allergic reactions, including anaphylaxis, have occurred in patients who were treated with VYONDYS 53. Additional allergic reactions, including rash, fever, itching, hives, and inflammation and/or peeling of the skin have occurred in patients who were treated with VYONDYS 53. Patients should seek immediate medical care should they experience signs and symptoms of allergic reaction. Your doctor will institute appropriate medical treatment which may include slowing, interrupting, or discontinuing the VYONDYS 53 infusion. Your doctor will monitor you until the condition resolves.

 

Kidney Toxicity and Monitoring: Damage to the kidneys was seen in animals who received golodirsen. Although damage to the kidneys was not seen in clinical studies with VYONDYS 53, potentially fatal kidney damage has occurred with other drugs that work in a similar way. Your doctor may recommend urine and blood testing before starting treatment followed by urine testing every month and a blood test every 3 months to monitor your kidneys.

Adverse Reactions: Side effects that have occurred in at least 20% of patients treated with VYONDYS 53 and more often than in patients who received an inactive intravenous (IV) infusion were headache (41%, 10%), fever (41%, 14%), fall (29%, 19%), pain in the abdomen (27%, 10%), infection of the nose and throat (27%, 14%), cough (27%, 19%), vomiting (27%, 19%), and nausea (20%, 10%).

Other side effects that occurred in greater than 5% of patients treated with VYONDYS 53 and more often than in patients who received an inactive IV infusion were pain at the IV site, back pain, pain, diarrhea, dizziness, stretch or tear in a ligament, bruising, flu, pain in the mouth and throat, stuffy or runny nose, scrapes or scratches of the skin, ear infection, seasonal allergy, fast heartbeat, reactions related to the IV catheter site, constipation, and broken bones.

What do I do if I have side effects?
Ask your healthcare provider for advice about any side effects that concern you.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).

The information provided here does not include all that is known about VYONDYS 53. To learn more, talk with your healthcare provider.

Before receiving this infusion, please see the full Prescribing Information for VYONDYS 53 (golodirsen).